205 related articles for article (PubMed ID: 10072445)
1. Ubiquitous induction of p53 in tumor cells by antisense inhibition of MDM2 expression.
Chen L; Lu W; Agrawal S; Zhou W; Zhang R; Chen J
Mol Med; 1999 Jan; 5(1):21-34. PubMed ID: 10072445
[TBL] [Abstract][Full Text] [Related]
2. Apoptosis of tumoral and nontumoral lymphoid cells is induced by both mdm2 and p53 antisense oligodeoxynucleotides.
Capoulade C; Mir LM; Carlier K; Lécluse Y; Tétaud C; Mishal Z; Wiels J
Blood; 2001 Feb; 97(4):1043-9. PubMed ID: 11159535
[TBL] [Abstract][Full Text] [Related]
3. Synergistic activation of p53 by inhibition of MDM2 expression and DNA damage.
Chen L; Agrawal S; Zhou W; Zhang R; Chen J
Proc Natl Acad Sci U S A; 1998 Jan; 95(1):195-200. PubMed ID: 9419352
[TBL] [Abstract][Full Text] [Related]
4. MDM2 oncogene as a target for cancer therapy: An antisense approach.
Wang H; Zeng X; Oliver P; Le LP; Chen J; Chen L; Zhou W; Agrawal S; Zhang R
Int J Oncol; 1999 Oct; 15(4):653-60. PubMed ID: 10493945
[TBL] [Abstract][Full Text] [Related]
5. Nuclear exclusion of p53 in a subset of tumors requires MDM2 function.
Lu W; Pochampally R; Chen L; Traidej M; Wang Y; Chen J
Oncogene; 2000 Jan; 19(2):232-40. PubMed ID: 10645001
[TBL] [Abstract][Full Text] [Related]
6. Altered expression of the cell cycle regulatory molecules pRb, p53 and MDM2 exert a synergetic effect on tumor growth and chromosomal instability in non-small cell lung carcinomas (NSCLCs).
Gorgoulis VG; Zacharatos P; Kotsinas A; Mariatos G; Liloglou T; Vogiatzi T; Foukas P; Rassidakis G; Garinis G; Ioannides T; Zoumpourlis V; Bramis J; Michail PO; Asimacopoulos PJ; Field JK; Kittas C
Mol Med; 2000 Mar; 6(3):208-37. PubMed ID: 10965496
[TBL] [Abstract][Full Text] [Related]
7. Anti-tumor efficacy of a novel antisense anti-MDM2 mixed-backbone oligonucleotide in human colon cancer models: p53-dependent and p53-independent mechanisms.
Wang H; Nan L; Yu D; Lindsey JR; Agrawal S; Zhang R
Mol Med; 2002 Apr; 8(4):185-99. PubMed ID: 12149568
[TBL] [Abstract][Full Text] [Related]
8. Experimental therapy of human prostate cancer by inhibiting MDM2 expression with novel mixed-backbone antisense oligonucleotides: in vitro and in vivo activities and mechanisms.
Wang H; Yu D; Agrawal S; Zhang R
Prostate; 2003 Feb; 54(3):194-205. PubMed ID: 12518324
[TBL] [Abstract][Full Text] [Related]
9. MDM2 mediated nuclear exclusion of p53 attenuates etoposide-induced apoptosis in neuroblastoma cells.
Rodriguez-Lopez AM; Xenaki D; Eden TO; Hickman JA; Chresta CM
Mol Pharmacol; 2001 Jan; 59(1):135-43. PubMed ID: 11125034
[TBL] [Abstract][Full Text] [Related]
10. MDM2 protein confers the resistance of a human glioblastoma cell line to cisplatin-induced apoptosis.
Kondo S; Barnett GH; Hara H; Morimura T; Takeuchi J
Oncogene; 1995 May; 10(10):2001-6. PubMed ID: 7761100
[TBL] [Abstract][Full Text] [Related]
11. Enhancement of drug-induced apoptosis by antisense oligodeoxynucleotides targeted against Mdm2 and p21WAF1/CIP1.
Sato N; Mizumoto K; Maehara N; Kusumoto M; Nishio S; Urashima T; Ogawa T; Tanaka M
Anticancer Res; 2000; 20(2A):837-42. PubMed ID: 10810363
[TBL] [Abstract][Full Text] [Related]
12. Abnormal expression of MDM2 in prostate carcinoma.
Leite KR; Franco MF; Srougi M; Nesrallah LJ; Nesrallah A; Bevilacqua RG; Darini E; Carvalho CM; Meirelles MI; Santana I; Camara-Lopes LH
Mod Pathol; 2001 May; 14(5):428-36. PubMed ID: 11353053
[TBL] [Abstract][Full Text] [Related]
13. Increased apoptosis induction by 121F mutant p53.
Saller E; Tom E; Brunori M; Otter M; Estreicher A; Mack DH; Iggo R
EMBO J; 1999 Aug; 18(16):4424-37. PubMed ID: 10449408
[TBL] [Abstract][Full Text] [Related]
14. Translational enhancement of mdm2 oncogene expression in human tumor cells containing a stabilized wild-type p53 protein.
Landers JE; Cassel SL; George DL
Cancer Res; 1997 Aug; 57(16):3562-8. PubMed ID: 9270029
[TBL] [Abstract][Full Text] [Related]
15. Rescue of K562 cells from MDM2-modulated p53-dependent apoptosis by growth factor-induced differentiation.
Mahdi T; Alcalay D; Cognard C; Tanzer J; Kitzis A
Biol Cell; 1998 Dec; 90(9):615-27. PubMed ID: 10085538
[TBL] [Abstract][Full Text] [Related]
16. Mdm2 ligase dead mutants did not act in a dominant negative manner to re-activate p53, but promoted tumor cell growth.
Swaroop M; Sun Y
Anticancer Res; 2003; 23(4):3167-74. PubMed ID: 12926050
[TBL] [Abstract][Full Text] [Related]
17. The roles of E6-AP and MDM2 in p53 regulation in human papillomavirus-positive cervical cancer cells.
Traidej M; Chen L; Yu D; Agrawal S; Chen J
Antisense Nucleic Acid Drug Dev; 2000 Feb; 10(1):17-27. PubMed ID: 10726657
[TBL] [Abstract][Full Text] [Related]
18. Enhanced translation: a novel mechanism of mdm2 oncogene overexpression identified in human tumor cells.
Landers JE; Haines DS; Strauss JF; George DL
Oncogene; 1994 Sep; 9(9):2745-50. PubMed ID: 8058341
[TBL] [Abstract][Full Text] [Related]
19. Survivin regulates the p53 tumor suppressor gene family.
Wang Z; Fukuda S; Pelus LM
Oncogene; 2004 Oct; 23(49):8146-53. PubMed ID: 15361831
[TBL] [Abstract][Full Text] [Related]
20. Cytoplasmically "sequestered" wild type p53 protein is resistant to Mdm2-mediated degradation.
Zaika A; Marchenko N; Moll UM
J Biol Chem; 1999 Sep; 274(39):27474-80. PubMed ID: 10488081
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
